Cherry Hill Mortgage Investment Corp. (CHMI) Financials Nov

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Cherry Hill Mortgage Investment Corp. (CHMI) Financials Nov 20, 2014, 4:02 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Cherry Hill Mortgage Investment Corp.


Fiscal year is January-December. All values USD millions. 2012 2013 5-year trend
Sales/Revenue - - - 0 5.01M
Total Investment Income - - - 0 (527,000)
Sundry Revenue/Income - - - 0 59,000
Trading Account Income - - - 0 -
Trust Income, Commissions & Fees - - - 0 -
Commission & Fee Income - - - 0 -
Total Expense - - - 25,000 (16.2M)
Total Interest Expense - - - - 867,000
Depreciation & Amortization Expense - - - 0 0
Other Operating Expense - - - 0 (18.39M)
2012 2013 5-year trend
Operating Income - - - (25,000) 21.2M
Non-Operating Income (Expense) - - - 0 0
Non-Operating Interest Income - - - - 0
Miscellaneous Non Operating Expense - - - 0 0
Equity in Affiliates (Pretax) - - - 0 -
Unusual Expense - - - 0 0
Pretax Income - - - (25,000) 21.2M
Income Taxes - - - 0 0
Income Tax - Current - Domestic - - - 0 -
Income Tax - Current - Foreign - - - 0 -
Income Tax - Deferred - Domestic - - - 0 -
Income Tax - Deferred - Foreign - - - 0 -
Income Tax Credits - - - 0 -
Equity in Affiliates - - - 0 0
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income - - - (25,000) 21.2M
Minority Interest Expense - - - 0 107,000
Net Income - - - (25,000) 21.1M
Extraordinaries & Discontinued Operations - - - 0 0
Extra Items & Gain/Loss Sale Of Assets - - - 0 0
Cumulative Effect - Accounting Chg - - - - 0
Discontinued Operations - - - 0 0
Net Income After Extraordinaries - - - (25,000) 21.1M
Preferred Dividends - - - 0 0
Net Income Available to Common - - - (25,000) 21.1M
EPS (Basic) - - - () 12.50
Basic Shares Outstanding - - - 7.5M 1.69M
EPS (Diluted) - - - () 12.50
Diluted Shares Outstanding - - - 7.5M 1.69M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Exploring Advances in AI and Digital R&D Innovation by ICON plc

Updated Category News Views 227

Recent Developments in AI and Digital Innovation by ICON plc ICON plc, a globally recognized clinical research organization (NASDAQ: ICLR), has recently conducted an extensive survey exploring the integration of Artificial Intelligence (AI) and digital tools within clinical research. Engaging with over 100 professionals in the biotech and pharmaceutical industries across...

Continue Reading
Tesla's Self-Driving Claims Under Fire: Industry Reactions

Updated Category News Views 167

Tesla's License Suspension in California Recently, a court in California announced a significant development affecting Tesla Inc. (NASDAQ: TSLA). The court decided to suspend Tesla's license to sell vehicles for 30 days due to a lawsuit concerning misleading claims about the company's Full Self-Driving (FSD) technology. If Tesla does not adapt its policies within 90 days,...

Continue Reading
Sunnova Energy Faces Challenges Amid Revenue Declines in 2024

Updated Category News Views 384

Sunnova Energy Experiences Financial Struggles Sunnova Energy International Inc. (NOVA) has encountered a challenging period, with its shares trading lower in the premarket on Monday following a disappointing report detailing its fourth quarter and full-year financial results. The financial landscape for Sunnova shows a revenue of $224.127 million, which unfortunately...

Continue Reading
Kerusso's Important Contributions in Faith and Community Work

Updated Category News Views 133

Kerusso's Inspiring Charitable Contributions in 2025 Kerusso Activewear, a prominent Christian apparel and gift brand, has ended the year with a remarkable achievement of over $400,000 in charitable contributions. This reflects their steadfast commitment to enriching lives through faith-based approaches and generous support for individuals in need. Growing Demand for...

Continue Reading
Prelude Therapeutics and Incyte Join Forces for JAK2JH2 Inhibitor

Updated Category News Views 101

Prelude Therapeutics Partners with Incyte on JAK2V617F Program Incyte establishes exclusive option to acquire Prelude’s innovative programs These inhibitors have the potential to modify disease outcomes in patients with myeloproliferative neoplasms (MPNs) Prelude Therapeutics, a clinical-stage oncology company, has recently made headlines with an exciting announcement...

Continue Reading